However, currently, for Luminal [estrogen receptors (ER) positive] BC with metastatic LNs, it is recommended an extension of endocrine therapy towards a duration of 10 years based on persistent risks of recurrence among such patients [5,6,11]. This evidence concerns the gene ESR1 and breast cancer.